

Isis Pharmaceuticals develops novel drugs for the treatment of cardiovascular, metabolic, severe and rare diseases. Among its major competitors, Isis Pharmaceuticals is ranked in 6th place for NPS while Alnylam Pharmaceuticals is 1st, and Amgen is 2nd.